SCR-LIP-000760 · Claim · machine-readable JSON →

Genetic findings in lipedema include variants and loci in hormone-related pathways, notably steroid hormone metabolism.

General proposition consolidated from 6 earlier single-paper claims; each study's own result is shown as its finding.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
moderate (GRADE)
Evidence
6 source(s)
Dates
2026-11-20 → 2026-11-20

Structured evidence, machine-compiled — not a verdict.

Evidence over time

20202026Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema — Michelini et al. (2020) · consistentInvestigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort — Grigoriadis et al. (2021) · consistentLipedema Research—Quo Vadis? — Ernst et al. (2023) · contextualGenome-wide association study of a lipedema phenotype among women in the UK Biobank identifies multiple genetic risk factors — Klimentidis et al. (2023) · consistentLipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025) · consistentFrom rare familial mutations to multifactorial disease: aldo-keto reductase 1C enzymes as a central biological pathway in lipedema — Vainberg et al. (2026) · consistent

Evidence (6)

Context (PECO)

Populationfamily members with autosomal dominant primary lipedema
Conditionlipedema
ExposureAKR1C1 c.638T>A (p.L213Q) variant
Comparatorunaffected family members without variant
Outcomelipedema disease segregation and 20α-HSD function prediction
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Change log